These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 864758)

  • 21. The role of complete Freund's adjuvant in the immunoprotection of L2C guinea pig leukemia.
    Ellman L; Green I
    Proc Soc Exp Biol Med; 1971 Nov; 138(2):566-70. PubMed ID: 5118467
    [No Abstract]   [Full Text] [Related]  

  • 22. Immunization of guinea pigs against L2C leukemia with live leukemic cells by intradermal inoculation: early and late effects.
    Gross L; Dreyfuss Y
    Fed Proc; 1977 Aug; 36(9):2272-6. PubMed ID: 885263
    [No Abstract]   [Full Text] [Related]  

  • 23. Modulation of host immune response against the L2C guinea pig leukemia.
    Klein DL; Pearson JW
    Fed Proc; 1977 Aug; 36(9):2276-80. PubMed ID: 885264
    [No Abstract]   [Full Text] [Related]  

  • 24. Discussion paper: loss of antigenicity associated with deletion of Ia alloantigens in a mutant line of guinea pig L2C leukemia.
    Forni G; Shevach EM; Green I
    Ann N Y Acad Sci; 1976; 276():381-5. PubMed ID: 1071968
    [No Abstract]   [Full Text] [Related]  

  • 25. New data on the cytolytic effects of natural killer cells (Kurloff cells) on a leukemic cell line (guinea pig L2C).
    Debout C; Quillec M; Izard J
    Leuk Res; 1999 Feb; 23(2):137-47. PubMed ID: 10071129
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monoclonal antibodies to guinea pig Ia antigens. I. Production, serologic, and immunochemical characterization.
    Burger R; Clement L; Schroer J; Chiba J; Shevach EM
    J Immunol; 1981 Jan; 126(1):32-7. PubMed ID: 6935294
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increase of a guinea pig natural killer cell (Kurloff cell) during leukemogenesis.
    Debout C; Taouji S; Izard J
    Cancer Lett; 1995 Oct; 97(1):117-22. PubMed ID: 7585470
    [TBL] [Abstract][Full Text] [Related]  

  • 28. More on the relevance of animal tumor models: immunogenicity of transplantable leukemias of recent origin in syngeneic strain 2 guinea pigs.
    Key ME; Brandhorst JS; Hanna MG
    J Biol Response Mod; 1984 Aug; 3(4):359-65. PubMed ID: 6481400
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of a model of chronic lymphocytic leukemia in inbred strain 2 guinea pigs.
    Key ME; Brandhorst JS; Bucana CD; Hanna MG
    J Natl Cancer Inst; 1983 Jun; 70(6):1139-49. PubMed ID: 6574284
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Guinea pigs sublethally infected with aerosolized Legionella pneumophila develop humoral and cell-mediated immune responses and are protected against lethal aerosol challenge. A model for studying host defense against lung infections caused by intracellular pathogens.
    Breiman RF; Horwitz MA
    J Exp Med; 1987 Mar; 165(3):799-811. PubMed ID: 3819647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of the oncornavirus particles in the plasma of guinea pigs with L2C leukemia.
    Michalides R; Scholom J; Pearson J; Perk K; Dahlberg J
    J Virol; 1976 Jun; 18(3):1120-30. PubMed ID: 58078
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of L2C leukemia on macrophage-mediated responses.
    Collins DP
    Cancer Immunol Immunother; 1987; 25(2):75-80. PubMed ID: 2822244
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Responses of tumors induced in inbred guinea pig strain JY=1 and strain Hartley/F to BCG.
    Kataoka T; Tokunaga T; Murohashi T
    J Natl Cancer Inst; 1977 Mar; 58(3):803-8. PubMed ID: 320348
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interference of preceding BCG vaccination with BCG immunotherapy in L2C-guinea pig leukemia.
    Dopatka HD; Majer M; Hennessen W; Mauler R
    Dev Biol Stand; 1977 Apr 13-15; 38():359-62. PubMed ID: 608524
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Generation of lymphokine-activated killer cells in strain 2 guinea pigs and their use in the therapy of L2C, an acute B-cell leukemia.
    Gregg EO; Gregg IC; Green I
    Cancer Res; 1987 Feb; 47(3):723-9. PubMed ID: 3492265
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BCG-immunotherapy of L2C-guinea pig leukemia.
    Dopatka HD; Majer M; Freudenstein H
    Eur J Cancer (1965); 1978 Feb; 14(2):169-81. PubMed ID: 624313
    [No Abstract]   [Full Text] [Related]  

  • 37. Guinea pig L2C leukemia: immunological, virological and clinical aspects: introduction.
    Rhim JS; Green I
    Fed Proc; 1977 Aug; 36(9):2247-8. PubMed ID: 195844
    [No Abstract]   [Full Text] [Related]  

  • 38. The use of immunotherapy to enhance tumor rejection immunity in leukemic (L2C) guinea pigs following remission induction with MeCCNU.
    Klein DL; Cote P; Garner W; Wallen RM; Pearson JW
    Leuk Res; 1980; 4(1):185-95. PubMed ID: 7412356
    [No Abstract]   [Full Text] [Related]  

  • 39. Preferential expression of IgG1 antibodies specific for L2C leukaemia IgM idiotypic determinants in tumour-protected strain 2 guinea-pigs.
    Ricardo MJ; Grimm DT
    Immunology; 1983 Apr; 48(4):763-9. PubMed ID: 6187671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genealogy of the L2C leukemia "lines" in the strain 2 guinea pig.
    Nadel EM
    J Natl Cancer Inst; 1977 May; 58(5):1183. PubMed ID: 853521
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.